Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher to Collaborate on Peptide Studies with Belfast Researchers

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said today that it will collaborate with the Molecular Therapeutics Research Group at the School of Pharmacy, Queen’s University Belfast, to analyze peptides within amphibian venom.
 
The research group is using Thermo Fisher’s LTQ Orbitrap XL mass spectrometer on a trial basis for complex peptide identification and for generating data needed for the de novo sequencing of peptides. The group is currently working on the isolation, structural characterization, and functional evaluation of novel peptides extracted from amphibian, snake, and arthropod venoms.
 
The research, conducted by Chris Shaw and colleagues, is aimed at discovering novel peptide drug discovery leads.
 
Shaw said in a statement that the Orbitrap technology “has enabled us to determine that the synthetic replicate produced in analysis is highly accurate in terms of molecular characterization identical to the natural compound.” He claimed this is the first time a proteomics instrument has been able to achieve this feat, which means that “we can avoid the possibility of working for years on fruitless research.”

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.